键琴
发表于 2025-3-28 16:24:34
http://reply.papertrans.cn/20/1906/190570/190570_41.png
鞭子
发表于 2025-3-28 22:24:24
http://reply.papertrans.cn/20/1906/190570/190570_42.png
Aura231
发表于 2025-3-28 23:49:35
http://reply.papertrans.cn/20/1906/190570/190570_43.png
独特性
发表于 2025-3-29 06:42:18
https://doi.org/10.1007/978-3-319-99510-6to discuss the value and the role of integrated oncological care in the era of oncology sub-specializations. Additionally, it sheds light on how the harmonization across the health providers can enhance patient care in this setting.
Encumber
发表于 2025-3-29 11:19:22
http://reply.papertrans.cn/20/1906/190570/190570_45.png
Overthrow
发表于 2025-3-29 13:40:15
http://reply.papertrans.cn/20/1906/190570/190570_46.png
allude
发表于 2025-3-29 17:09:02
http://reply.papertrans.cn/20/1906/190570/190570_47.png
补助
发表于 2025-3-29 21:40:14
https://doi.org/10.1007/978-981-15-9158-7t options based on tumour patterns and a patient-centred approach. A proper patient’s selection is crucial to derive maximal benefits from a treatment strategy and emerging biomarkers should be integrated along with the HER2 status, which is currently the only validated biomarker in the context of H
忍耐
发表于 2025-3-30 00:58:54
https://doi.org/10.1007/978-981-15-9158-7and many trials specifically designed for this population are currently ongoing. The BC research community needs to address this call with the final aim of improving the efficacy of systemic therapy in CNS compartment and ultimately preventing the occurrence of BM.
敌意
发表于 2025-3-30 06:47:04
https://doi.org/10.1007/978-981-15-9158-7ing. The aim of this chapter is to review all types of cardiotoxic manifestations related to novel and old agents approved for treatment of BC patients including chemotherapy, anti-HER2 agents, cyclin-dependent kinase 4/6 inhibitors, PolyADP-ribose polymerase (PARP) inhibitors, antiangiogenic drugs